Drugs Rules 1945 amendment: India simplifies import of small-quantity drugs for testing
Synopsis
India's Health Ministry is scrapping the licensing requirement for importing small drug quantities meant for testing and R&D, replacing it with a simple online acknowledgement system. Building on a January 2026 domestic reform, the move targets a long-standing bottleneck that has slowed pharma start-ups and research labs — with carve-outs for high-risk categories like narcotics and biologics.
Key Takeaways
The Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945 to simplify drug imports for testing and analysis under Form 11 .
A new acknowledgement-based system will replace prior licensing requirements for small-quantity imports meant for analytical and non-clinical testing.
Excluded categories — including narcotic and psychotropic substances , cytotoxic drugs , and biologics with live microorganisms — will still require prior licensing.
The amendment extends a similar notification system already introduced for domestic test licences in January 2026 under the New Drugs and Clinical Trials Rules, 2019.
Stakeholders can submit objections or suggestions to the Under Secretary (Drugs) , Ministry of Health and Family Welfare.
The Union Ministry of Health and Family Welfare on Friday, 26 June announced proposed amendments to the Drugs Rules, 1945 that would simplify the procedure for importing drugs in small quantities for examination, testing, or analysis — a process currently governed by Form 11. The move is aimed at reducing the regulatory burden on pharmaceutical companies, start-ups, and research institutions seeking to import drugs solely for analytical or non-clinical testing purposes.
What the Amendment Proposes
The revised framework introduces an acknowledgement-based system, replacing the existing licensing requirement for importing small quantities of drugs for testing and research and development (R&D) purposes. Under the proposed provisions, applicants must submit a prior intimation form online. Import can then proceed based on the acknowledgement automatically generated upon submission — eliminating the need for prior licensing in most cases.
The online intimation system is designed to function as a seamless, near-instant gateway for industry stakeholders, significantly cutting down processing delays that have historically slowed early-stage pharmaceutical research.
Which Drugs Are Excluded
The simplified procedure will not apply to all drug categories. According to the ministry, imports of sex hormones, cytotoxic drugs, beta lactam drugs, biologics containing live microorganisms, and narcotic and psychotropic substances will continue to require prior licensing. These exclusions reflect existing regulatory caution around substances with higher misuse potential or complex handling requirements.
Context and Background
This proposed import amendment builds on an earlier regulatory reform: the Ministry of Health and Family Welfare had already amended the New Drugs and Clinical Trials Rules, 2019 in January 2026, introducing a comparable notification-based system for domestic test licences. The current proposal extends that logic to the import side, creating a more consistent regulatory architecture across domestic and cross-border procurement of test quantities.
Notably, India's pharmaceutical sector — the world's third-largest by volume — has long flagged procedural delays in obtaining import permissions as a barrier to faster R&D cycles. This comes amid the government's broader push to position India as a global hub for pharmaceutical innovation and generic drug manufacturing.
Impact on Industry and Start-Ups
The amendment is expected to particularly benefit pharmaceutical start-ups and smaller research organisations that lack the administrative bandwidth to navigate lengthy licensing procedures. By enabling quick initiation of testing or analysis, the change could compress product development timelines and reduce early-stage compliance costs.
According to the official statement, the amendment aligns with the government's continued efforts to improve the regulatory ecosystem, promote ease of doing business, and foster innovation in the pharmaceutical sector.
Stakeholder Consultation
The proposed amendment is currently in the public consultation phase. Stakeholders wishing to submit objections or suggestions on the draft legislation may do so by writing to the Under Secretary (Drugs), Ministry of Health and Family Welfare. No deadline for submissions was specified in the ministry's statement.
If finalised, the amendment would represent a meaningful step toward streamlining India's pharmaceutical regulatory framework and accelerating the country's research and innovation pipeline.
Point of View
But its significance lies in what it signals: the government is finally treating early-stage pharmaceutical research as a priority, not a compliance exercise. India's R&D intensity in pharma remains low relative to its manufacturing scale, and import delays for test quantities have been a quiet but persistent drag. The real test will be whether the online system is genuinely instant or merely digitises the old queue. The January 2026 domestic reform gives some grounds for cautious optimism — but the exclusion list, particularly around biologics, is broad enough to limit the amendment's reach for cutting-edge research areas like cell and gene therapy.
NationPress
26 Jun 2026
Frequently Asked Questions
What change has the Health Ministry proposed to drug import rules?
The Ministry of Health and Family Welfare has proposed amending the Drugs Rules, 1945 to replace the prior licensing requirement for importing small quantities of drugs with an acknowledgement-based system. Applicants will submit an online prior intimation form and can proceed with the import once an acknowledgement is generated.
Which drugs are excluded from the simplified import procedure?
The simplified procedure does not apply to sex hormones, cytotoxic drugs, beta lactam drugs, biologics containing live microorganisms, and narcotic and psychotropic substances. These categories will continue to require prior licensing before import.
How does this amendment relate to the January 2026 reform?
In January 2026, the ministry had already introduced a notification-based system for domestic test licences under the New Drugs and Clinical Trials Rules, 2019. The current proposed amendment extends the same acknowledgement-based logic to drug imports, creating a consistent framework across domestic and cross-border procurement.
Who benefits most from this change?
Pharmaceutical start-ups, smaller research organisations, and industries conducting early-stage R&D stand to benefit most. The removal of licensing requirements reduces compliance burden and allows faster initiation of testing or analysis, particularly for entities with limited administrative resources.
How can stakeholders respond to the proposed amendment?
Stakeholders can submit their objections and suggestions on the draft legislation to the Under Secretary (Drugs), Ministry of Health and Family Welfare. The ministry has not specified a deadline for submissions in its official statement.
